Orange Book product · Generic (ANDA)
NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE
At a glance
Nov 07, 2018
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 07, 2018
7 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
NOREPINEPHRINE BITARTRATE
Strength
EQ 1MG BASE/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 203662
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of NOREPINEPHRINE BITARTRATE
- 2026NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEBrand (NDA)
NDA 214313 · BAXTER HLTHCARE CORP
- 2022NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEBrand (NDA)
NDA 214628 · LONG GROVE PHARMS
- 2022NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEBrand (NDA)
NDA 215700 · INFORLIFE
- —LEVOPHEDBrand (NDA)
NDA 007513 · HOSPIRA
- 2026NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 216272 · NEPHRON
- 2026NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEGeneric (ANDA)
ANDA 220483 · SAGENT
- 2025NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 218595 · MSN
- 2025NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 219924 · ANTHEA PHARMA
- 2025NOREPINEPHRINE BITARTRATE IN 5% DEXTROSEGeneric (ANDA)
ANDA 219692 · SAGENT
- 2025NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 219443 · BIOCON PHARMA
- 2025NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 219163 · ASPIRO
- 2024NOREPINEPHRINE BITARTRATEGeneric (ANDA)
ANDA 218758 · RISING
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
